Bioinformatics investigation of the prognostic value and mechanistic role of CD9 in glioma DOI Creative Commons
Jing Jiang, Bo Jiang, Wenbin Li

и другие.

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Окт. 18, 2024

In recent years, CD9 has been extensively studied as a potential biomarker for cancer. However, the biological role of in gliomas remains unclear. This study investigates function and its molecular mechanisms. Utilizing pan-cancer analysis with TCGA, CGGA, GEO databases, differential expression was observed 11 tumor types within TCGA cohort, it associated patient survival rates. Analysis CGGA glioma database revealed that patients high had lower The area under ROC curve (AUC) GSE16011 greater than 0.7, indicating discriminative ability. Through gene set enrichment (GSEA), immune-related analysis, mutation detection, found to have strongest correlation neutrophil involvement (cor = 0.30, P < 0.05), group exhibited higher rejection responses TIDE scores, suggesting likelihood successful immunotherapy. more sensitive 81 drugs, therapeutic effects gliomas. Furthermore, overexpression may be mutations. Down-regulation or up-regulation glioblastoma cell line LN229 showed could positively regulate migratory ability cells. Further, several marker genes, such VEGFR-2, TGF-β1, CASP1 PI3K, were down regulated knockdown lines up lines, compared control line. preliminarily explores prognostic value, providing new insights personalized treatment strategies therapy.

Язык: Английский

Navigating the Brain: Harnessing Endogenous Cellular Hitchhiking for Targeting Neoplastic and Neuroinflammatory Diseases DOI Creative Commons

Suraj Wagh,

Paras Famta,

Saurabh Shah

и другие.

Asian Journal of Pharmaceutical Sciences, Год журнала: 2025, Номер unknown, С. 101040 - 101040

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

1
Immune Cell Interplay in the Fight Against GBM DOI Open Access

Nico Vallieri,

Angeliki Datsi

Cancers, Год журнала: 2025, Номер 17(5), С. 817 - 817

Опубликована: Фев. 26, 2025

Despite multimodal therapies, the treatment of glioblastoma remains challenging. In addition to very complex mechanisms cancer cells, including specialized phenotypes that enable them proliferate, invade tissues, and evade immunosurveillance, they exhibit a pronounced resistance chemo- radiotherapy. More advanced tumors create hypoxic environment supports their proliferation survival, while robust angiogenesis ensures constant supply nutrients. GBM, these structures are contribute creation maintenance highly immunosuppressive microenvironment promotes tumor growth immune escape. addition, high accumulation tumor-infiltrating leukocytes other expression checkpoint molecules, low mutational burden, i.e., number neoantigens, hallmarks GBM challenge therapeutic approaches. Here, we review exploits support potential treatments. These include new chemotherapeutics, treating fields, small compounds targeting or blockers tyrosine kinases inhibit cell survival. focus on immunotherapies such as blockade in particular vaccination with dendritic cells CAR-T which can either kill directly bypass immunosuppression by modulating boosting patient's own response.

Язык: Английский

Процитировано

0
Novel neutrophil targeting platforms in treating Glioblastoma: Latest evidence and therapeutic approaches DOI
Rui Zhong,

Hongmei He,

X Wang

и другие.

International Immunopharmacology, Год журнала: 2025, Номер 150, С. 114173 - 114173

Опубликована: Фев. 11, 2025

Язык: Английский

Процитировано

0
Opportunities to Modulate Tumor Ecosystem Toward Successful Glioblastoma Immunotherapy DOI Creative Commons
Mariko Takahashi,

Darina Mukhamejanova,

Himani Jasewicz

и другие.

Cancer Science, Год журнала: 2025, Номер unknown

Опубликована: Март 23, 2025

Over the past decade, failure of multiple clinical trials has confirmed need for a systematic and comprehensive understanding glioblastoma (GBM). Current immunotherapies aiming to harness immune system achieve anti-tumor effects remain largely ineffective, highlighting complexities GBM microenvironment. However, our recent niches within central nervous provides both opportunities challenges in translating these insights into successful immunotherapy implementation. We discuss strategies, including targeting antigens heterogeneous microenvironment, identifying new druggable targets abrogate immunosuppression, niche-specific cell functionality modulate tumor-immune-stroma interactions.

Язык: Английский

Процитировано

0
Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma DOI
Johnny Duerinck,

Louise Lescrauwaet,

Iris Dirven

и другие.

Neuro-Oncology, Год журнала: 2024, Номер 26(12), С. 2208 - 2221

Опубликована: Окт. 16, 2024

Abstract Background Recurrent high-grade glioma (rHGG) lacks effective life-prolonging treatments and the efficacy of systemic PD-1 CTLA-4 immune checkpoint inhibitors is limited. The multi-cohort Glitipni phase I trial investigates safety feasibility intraoperative intracerebral (iCer) postoperative intracavitary (iCav) nivolumab (NIVO) ± ipilimumab (IPI) treatment following maximal safe resection (MSR) in rHGG. Materials methods Patients received 10 mg IV NIVO within 24 h before surgery, followed by MSR, iCer 5 IPI NIVO, Ommaya catheter placement cavity. Biweekly iCav administrations 1–5–10 (cohort 4) or plus 7) were combined with for 11 cycles. Results 42 rHGG patients underwent MSR + IPI. 16 pts treated cohort 4 (postoperative at escalating doses) while 28 7 (intra doses IPI). most common TRAE was fatigue; no grade AE occurred. Dose-limiting toxicity 3 neutrophilic pleocytosis (4 pts) receiving PFS OS did not significantly differ between cohorts (median OS: [95% CI 26–57] vs. 35 [29–40] weeks; 1-year rate: 37% 29%). Baseline B7–H3 expression correlated worse survival. compared favorably to a historical pooled (n = 469) Belgian anti-VEGF therapies (log-rank P .015). Conclusion Intraoperative up biweekly 1 feasible safe, showing encouraging patients. ClinicalTrials.gov registration: NCT03233152

Язык: Английский

Процитировано

3
Cryoablation-induced neutrophil Ca2+ elevation and NET formation exacerbate immune escape in colorectal cancer liver metastasis DOI Creative Commons

Hongtong Tan,

Yiquan Jiang,

Lujun Shen

и другие.

Journal of Experimental & Clinical Cancer Research, Год журнала: 2024, Номер 43(1)

Опубликована: Дек. 9, 2024

Язык: Английский

Процитировано

2
Complement C1S is a potential prognostic biomarker and associated with M2 macrophage infiltration in gliomas: From bioinformatics to comprehensive experimental validation DOI
Lun Gao, Xuefang Jing,

Qiuwei Hua

и другие.

International Immunopharmacology, Год журнала: 2024, Номер 143, С. 113573 - 113573

Опубликована: Ноя. 7, 2024

Язык: Английский

Процитировано

1
The Systemic Inflammation Response Index Efficiently Discriminates between the Failure Patterns of Patients with Isocitrate Dehydrogenase Wild-Type Glioblastoma Following Radiochemotherapy with FLAIR-Based Gross Tumor Volume Delineation DOI Creative Commons
Şükran Senyürek, Murat Serhat Aygün,

Nülifer Kılıç Durankuş

и другие.

Brain Sciences, Год журнала: 2024, Номер 14(9), С. 922 - 922

Опубликована: Сен. 15, 2024

The objective of this study was to assess the connection between systemic inflammation response index (SIRI) values and failure patterns patients with IDH wild-type glioblastoma (GB) who underwent radiotherapy (RT) FLAIR-based gross tumor volume (GTV) delineation.

Язык: Английский

Процитировано

0
Bioinformatics investigation of the prognostic value and mechanistic role of CD9 in glioma DOI Creative Commons
Jing Jiang, Bo Jiang, Wenbin Li

и другие.

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Окт. 18, 2024

In recent years, CD9 has been extensively studied as a potential biomarker for cancer. However, the biological role of in gliomas remains unclear. This study investigates function and its molecular mechanisms. Utilizing pan-cancer analysis with TCGA, CGGA, GEO databases, differential expression was observed 11 tumor types within TCGA cohort, it associated patient survival rates. Analysis CGGA glioma database revealed that patients high had lower The area under ROC curve (AUC) GSE16011 greater than 0.7, indicating discriminative ability. Through gene set enrichment (GSEA), immune-related analysis, mutation detection, found to have strongest correlation neutrophil involvement (cor = 0.30, P < 0.05), group exhibited higher rejection responses TIDE scores, suggesting likelihood successful immunotherapy. more sensitive 81 drugs, therapeutic effects gliomas. Furthermore, overexpression may be mutations. Down-regulation or up-regulation glioblastoma cell line LN229 showed could positively regulate migratory ability cells. Further, several marker genes, such VEGFR-2, TGF-β1, CASP1 PI3K, were down regulated knockdown lines up lines, compared control line. preliminarily explores prognostic value, providing new insights personalized treatment strategies therapy.

Язык: Английский

Процитировано

0